Medical Xpress August 2, 2024
CAR-T cells are highly effective in treating selected blood cancers. However, challenges remain with this new therapy, which was first approved in 2017 in the U.S. and a year later in Europe for treating acute lymphoblastic leukemia (ALL). For instance, no effective CAR-T cell therapies for solid tumors exist. Furthermore, CAR-T-induced remissions are not always durable, and the production of CAR-T cells is slow and laborious.
Dr. Karl Petri of the University Hospital Würzburg (UKW) / Julius-Maximilians-University Würzburg aims to address these issues using an advanced CRISPR method to increase the efficiency of cancer-directed immunotherapies.
Prime-CAR inspection project
His project is called Prime-CAR Inspection. “Prime” stands for the CRISPR 2.0 method CRISPR Prime Editing, which allows for targeted and programmable...
Today's Sponsors
Today's Sponsor